Bensimon, A. G. Et Al. 2020. Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma. CURRENT MEDICAL RESEARCH AND OPINION , vol.36, no.9 , 1507-1517.

Bensimon, A. G., Zhong, Y., Swami, U., Briggs, A., Young, J., Feng, Y., ... Song, Y.(2020). Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma. CURRENT MEDICAL RESEARCH AND OPINION , vol.36, no.9, 1507-1517.

Bensimon, Arielle Et Al. "Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma," CURRENT MEDICAL RESEARCH AND OPINION , vol.36, no.9, 1507-1517, 2020

Bensimon, Arielle G. Et Al. "Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma." CURRENT MEDICAL RESEARCH AND OPINION , vol.36, no.9, pp.1507-1517, 2020

Bensimon, A. G. Et Al. (2020) . "Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma." CURRENT MEDICAL RESEARCH AND OPINION , vol.36, no.9, pp.1507-1517.

@article{article, author={Arielle G. Bensimon Et Al. }, title={Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma}, journal={CURRENT MEDICAL RESEARCH AND OPINION}, year=2020, pages={1507-1517} }